公开(公告)号：US20250064750A1

公开(公告)日：2025-02-27

申请号：US18725552

申请日：2022-12-29

Applicant: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. ,  SHANGHAI SENHUI MEDICINE CO., LTD. ,  SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD.

Inventor： Lingjian ZHU ,  Jianyu SHI ,  Chongyi LIU ,  Jun JIANG ,  Jian HUANG

IPC: A61K9/51 ,  A61K31/7105 ,  C07C229/12

Abstract: Provided are a lipid and a composition used for delivery. Specifically provided is a compound represented by formula I or a salt thereof, wherein R1 to R3, H1 to H3, L1, and L2 are as defined in the description.

公开(公告)号：US20250051467A1

公开(公告)日：2025-02-13

申请号：US18683212

申请日：2022-08-24

Applicant: Jiangsu Hengrui Pharmaceuticals Co., Ltd. ,  Shanghai Shengdi Pharmaceutical Co., Ltd.

Inventor： Yuan Lin ,  Simeng Chen ,  Tingting Wu ,  Rongting Hu ,  Cheng Liao

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40

Abstract: An FAP/CD40 binding molecule and the medicinal use thereof. Specifically, provided are an FAP binding molecule, a CD40 binding molecule and an FAP/CD40 binding molecule, a method for preventing and treating diseases (such as tumors or cancers) using same, and the medicinal use thereof.

公开(公告)号：US20250049778A1

公开(公告)日：2025-02-13

申请号：US18722345

申请日：2022-12-23

Applicant: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. ,  SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.

Inventor： Gujun Xu ,  Weldong Lu ,  Junran Yang ,  Zhenxing Du ,  Qiyun Shao

IPC: A61K31/454 ,  C07D405/14

Abstract: A crystalline form of a GLP-1 receptor agonist and a preparation method therefor. The agonist is a compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxane-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxe-tan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid.

公开(公告)号：US20240382607A1

公开(公告)日：2024-11-21

申请号：US18290721

申请日：2022-07-22

Applicant: SHANGHAI SENHUI MEDICINE CO., LTD. ,  SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. ,  SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. ,  JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Inventor： Xing SUN ,  Changyong YANG ,  Jindong LIANG ,  Cheng LIAO

IPC: A61K47/68 ,  A61P35/00

Abstract: A drug conjugate of an Eribulin derivative. Specifically, provided are an HER2 antibody conjugate that is formed by binding the Eribulin derivative to structural domain II of HER2, a preparation method therefor, and a pharmaceutical application thereof. The present invention further relates to a method for treating a cancer by means of administration of an antibody-drug conjugate, and a composition.

公开(公告)号：US20240366809A1

公开(公告)日：2024-11-07

申请号：US18687804

申请日：2022-09-01

Applicant: TIANJIN HENGRUI MEDICINE CO., LTD. ,  JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Inventor： Mengzhe WANG ,  Shunguang ZHOU ,  Liang YU ,  Lidong WANG ,  Libo ZHAO ,  Jiyun SUN ,  Feihu GUO ,  Xin LI

IPC: A61K51/04 ,  A61P35/00 ,  C07B59/00

Abstract: An inhibitor of a prostate specific membrane antigen and a pharmaceutical use thereof. Specifically, the present solution belongs to the field of radiopharmaceuticals and relates to a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240269307A1

公开(公告)日：2024-08-15

申请号：US18288172

申请日：2022-04-26

Applicant: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. ,  SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.

Inventor： Yang YANG ,  Haoying ZHANG ,  Weikang TAO

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/68037 ,  A61K47/6849 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided are an anti-Nectin-4 antibody and an anti-Nectin-4 antibody-drug conjugate, and a medicinal user thereof. The anti-Nectin-4 antibody, and the anti-Nectin-4 antibody-drug conjugate as represented by general formula (Pc-L-Y-D) are involved, wherein Pc is the anti-Nectin-4 antibody, and L, Y, and n are as defined in the description.

公开(公告)号：US20240262866A1

公开(公告)日：2024-08-08

申请号：US18566074

申请日：2022-06-02

Applicant: Shanghai Senhui Medicine Co., Ltd. ,  Shanghai Shengdi Pharmaceutical Co., Ltd. ,  Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Inventor： Wei Jiang ,  Jian Huang ,  Junqiang Hu ,  Weicou Cao ,  Yinan Zhou

IPC: C07K7/64 ,  C07D207/08 ,  C07K1/107

CPC classification number: C07K7/64 ,  C07D207/08 ,  C07K1/1077

Abstract: The present disclosure relates to a method for preparing an anidulafungin derivative. In particular, the present disclosure relates to a method for preparing an anidulafungin derivative as represented by formula (I) and an intermediate thereof.

公开(公告)号：US20240209114A1

公开(公告)日：2024-06-27

申请号：US18288078

申请日：2022-04-25

Applicant: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. ,  SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD.

Inventor： Xiaofeng YANG ,  Jing WEN ,  Jingyang ZHANG ,  Caihong ZHOU ,  Cheng LIAO

IPC: C07K16/40 ,  A61K39/00 ,  A61P9/10

CPC classification number: C07K16/40 ,  A61P9/10 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/94

Abstract: An anti-MASP2 antibody, an antigen-binding fragment thereof and the medical use thereof. Specifically, provided are an anti-MASP2 antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof, a method for treating diseases such as IgA nephropathy and a related pharmaceutical use.

公开(公告)号：US20240189438A1

公开(公告)日：2024-06-13

申请号：US18264072

申请日：2022-01-28

Applicant: Shanghai Senhui Medicine Co., Ltd. ,  Shanghai Shengdi Pharmaceutical Co., Ltd. ,  Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Inventor： Lingjian Zhu ,  Min Hong ,  Manping Tang ,  Lu Su ,  Mengdie Deng ,  Jingyang Zhang ,  Wenming Ren ,  Kan Lin ,  Jian Huang ,  Cheng Liao ,  Lianshan Zhang

IPC: A61K47/68 ,  A61P19/02 ,  A61P37/02

CPC classification number: A61K47/6803 ,  A61K47/6845 ,  A61K47/6889 ,  A61P19/02 ,  A61P37/02

Abstract: A drug conjugate of a glucocorticoid receptor agonist, and an application thereof in medicine. Specifically, the present invention relates to an antibody-drug conjugate as represented by formula (I): Ab-(L-D)k (I), wherein Ab is an antibody or an antigen-binding fragment thereof, L is a linker covalently linking Ab to D, k is 1 to 20, and D is as represented by formula (II-A) or (II-B). The groups in the formulas are as defined in the description. The antibody-drug conjugate can effectively treat autoimmune diseases.

公开(公告)号：US20240016822A1

公开(公告)日：2024-01-18

申请号：US18257325

申请日：2021-12-24

Applicant: Shanghai Shengdi Pharmaceutical Co., Ltd. ,  Shanghai Senhui Medicine Co., Ltd. ,  Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Inventor： Daping XU ,  Changyong YANG ,  Cheng LIAO ,  Lianshan ZHANG ,  Jian HUANG

IPC: A61K31/675 ,  A61K31/473

CPC classification number: A61K31/675 ,  A61K31/473

Abstract: The present disclosure relates to the use of an NK1 antagonist prodrug compound and a 5-HT3 receptor antagonist. In particular, the present disclosure relates to the use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in combination with a 5-HT3 receptor antagonist in the preparation of a drug for preventing or treating nausea and/or vomiting.